Patents by Inventor Giulietta MARUGGI

Giulietta MARUGGI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELF-AMPLIFYING MESSENGER RNA
    Publication number: 20240301006
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an interferon effector.
    Type: Application
    Filed: December 21, 2021
    Publication date: September 12, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Giulietta MARUGGI, Jason William WESTERBECK, Dong YU
  • SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS
    Publication number: 20240189417
    Abstract: Provided herein are RNA that: are collectively self-amplifying in an intracellular environment, comprise N1-methyl-pseudouridines and uridines, and have a mole percentage or mole proportion of the N1-methylpseudouridines to the total of the uridines and the Ni-methylpseudouridines or a mole ration of the N1-methylpseudouridines to the uridines.
    Type: Application
    Filed: January 29, 2024
    Publication date: June 13, 2024
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Giulietta MARUGGI, Qiongman KONG, Varnika ROY, Dong YU, Meng ZHANG
  • SARS COV-2 SPIKE PROTEIN CONSTRUCT
    Publication number: 20230364219
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an antigen, in particular a Coronavirus antigen.
    Type: Application
    Filed: April 16, 2021
    Publication date: November 16, 2023
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Dong YU, Giulietta MARUGGI, Jason W. WESTERBECK, Jeffrey B. ULMER, Jason P. LALIBERTE, Kate LUISI, Lin QU
  • THERAPEUTIC VIRAL VACCINE
    Publication number: 20220273789
    Abstract: The present invention relates to viral Fc receptor or immunogenic fragments thereof for treating a viral infection in a subject and, in particular, a herpes vims infection. The present invention also relates to a heterodimer comprising or consisting of an Fc receptor from a HSV vims or an immunogenic fragment thereof and a binding partner from said HSV vims or a fragment thereof, for use in therapy.
    Type: Application
    Filed: July 20, 2020
    Publication date: September 1, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand BLAIS, Cindy CASTADO, Johann MOLS, Lionel SACCONNAY, Marie TOUSSAINT, Newton Muchugu WAHOME, Giulietta MARUGGI
  • HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS
    Publication number: 20220062409
    Abstract: Simian adenoviral vectors and RNA molecules, each encoding an immunogen of interest, can be sequentially administered to provide potent and long-lasting immunity.
    Type: Application
    Filed: December 13, 2019
    Publication date: March 3, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefania CAPONE, Nicolas Frederic DELAHAYE, Giulietta MARUGGI, Haifeng SONG